82,018 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Aquatic Capital Management LLC

Aquatic Capital Management LLC purchased a new position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 82,018 shares of the company's stock, valued at approximately $1,015,000. Aquatic Capital Management LLC owned about 0.05% of Wave Life Sciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in shares of Wave Life Sciences in the fourth quarter worth $67,000. Summit Investment Advisors Inc. lifted its position in Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock valued at $119,000 after acquiring an additional 2,308 shares in the last quarter. Westwood Wealth Management purchased a new position in shares of Wave Life Sciences in the fourth quarter worth $124,000. Raymond James Financial Inc. purchased a new stake in shares of Wave Life Sciences during the fourth quarter valued at $157,000. Finally, Victory Capital Management Inc. increased its holdings in Wave Life Sciences by 16.6% in the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company's stock worth $180,000 after buying an additional 2,073 shares in the last quarter. Institutional investors own 89.73% of the company's stock.

Wave Life Sciences Price Performance

Shares of NASDAQ:WVE traded down $0.49 during mid-day trading on Tuesday, reaching $7.24. 439,290 shares of the company traded hands, compared to its average volume of 1,244,726. Wave Life Sciences Ltd. has a 52 week low of $4.25 and a 52 week high of $16.74. The firm has a market cap of $1.11 billion, a PE ratio of -6.52 and a beta of -0.91. The company's 50 day moving average price is $8.10 and its 200-day moving average price is $11.36.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.34. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The business had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million. On average, research analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, March 26th. StockNews.com upgraded shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Wedbush began coverage on shares of Wave Life Sciences in a research note on Tuesday, April 8th. They set an "outperform" rating and a $18.00 target price for the company. Cantor Fitzgerald initiated coverage on Wave Life Sciences in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target on the stock. Finally, Jefferies Financial Group assumed coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective for the company. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $21.17.

Insiders Place Their Bets

In related news, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now owns 16,115 shares in the company, valued at approximately $157,443.55. This trade represents a 39.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company's stock.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.